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for the first time in humans for the treatment of AIP.
Methods:
In this phase I, open label, dose-escalation, multicenter clinical trial, four cohorts of 2 patients each received a single intravenous injection of the vector ranging from 5x10 11 to 1.8x10 13 genome copies/kg. Adverse events and changes in urinary PBG and ALA and in the clinical course of the disease were periodically evaluated prior and after treatment. Viral shedding, immune response against the vector and vector persistence in the liver were investigated.
Results: Treatment was safe in all cases. All patients developed anti-AAV5 neutralizing antibodies but no cellular responses against AAV5 or PBGD were observed. There was a trend towards a reduction of hospitalizations and heme treatments, although ALA and PBG levels remained unchanged. Vector genomes and transgene expression could be detected in the liver one year after therapy.
Conclusion: rAAV2/5-PBGD administration is safe but AIP metabolic correction was not achieved at the doses tested in this trial. Notwithstanding, the treatment had a positive impact in clinical outcomes in most patients.
Lay summary
Studies in an acute intermittent porphyria (AIP) animal model have shown that gene delivery of PBGD to hepatocytes using an adenoassociated virus vector (rAAV2/5-PBG) prevent mice from suffering porphyria acute attacks. In this phase I, open label, dose-escalation, multicenter clinical trial we show that the administration of rAAV2/5-PBGD to patients with severe AIP is safe but metabolic correction was not achieved at the doses tested; the treatment, however, had a positive but heterogeneous impact on clinical outcomes among treated patients and 2 out of 8 patients have stopped hematin treatment.
INTRODUCTION
Acute Intermittent Porphyria (AIP) is inherited as an autosomal dominant disorder of the heme biosynthesis pathway (1) (2) . AIP is caused by a defect in porphobilinogen deaminase (PBGD) gene which spans 10 kb in chromosome 11q23 (3) . More than 370 different mutations of PBGD have been described, including missense, nonsense and splicing mutations, as well as deletions and insertions (4, 5) .
Heme is synthesized in all body cells but mainly in erythroid cells and the liver. In AIP PBGD enzymatic activity is reduced to about 50% of normal leading to limited capacity to enhance heme synthesis upon increased biosynthetic demands in the liver (1-3). 5-aminolevulinic acid synthase (ALAS) is the initial and rate-limiting enzyme of heme biosynthesis. In the liver, ALAS1 enzyme mediates the reaction of glycine with succinyl-CoA to yield aminolevulinic acid (ALA), which is transformed into porphobilinogen (PBG) by aminolevulinic acid dehydratase. PBGD mediates the condensation of PBG to hydroxymethylbilane, which is processed in a stepwise manner to heme, which negatively controls ALAS1 expression. In AIP subjects the heme deficiency taking place under conditions of augmented heme requirements enhances hepatic ALAS1 activity leading to ALA and PBG accumulation (1-3). These compounds are believed to be responsible for the complex set of neurotoxic symptoms exhibited by AIP patients (6).
AIP is characterized by acute episodes and asymptomatic periods (1, 2, 6 men with AIP suffer recurrent and frequent attacks, which persist for many years (6).
This form of severe AIP is a devastating condition that significantly affects the quality of life and demands repeated courses of treatment with heme. Although heme represses ALAS, thus blocking heme biosynthesis, it also activates hemeoxygenase-1 (EC:1.14.99.3), which in turn promotes acute attack recurrences and the decline of the therapeutic efficacy (16, 17) . Thromboembolic disease and iron overload (a dose of 250 mg of heme arginate contains 22.7 mg of iron) are also side effects associated with repeated courses of this therapy (18) . Even though prophylactic heme appears to be beneficial in patients with recurrent attacks, life-long exposure to drugs for the control of symptoms may cause considerable adverse events that greatly impair quality of life (16, 17) . Thus alternative therapies for severe AIP are needed.
Complete biochemical and symptomatic resolution of AIP was observed in all patients after liver transplantation (19) . This observation supports our working hypothesis that therapies aimed at supplementing hepatocytes with the normal version of the PBGD gene may correct the disease. Confirming this notion, our studies in murine AIP models showed that liver-directed gene therapy using an AAV vector encoding PBGD under the control of a liver-specific promoter (rAAV2/5-PBGD) was able to restore hepatic PBGD activity to normal values and prevented the occurrence of acute attacks (20) .
Toxicology studies in mice (unpublished results) and in non-human primates (21) showed that the vector could be administered safely even at high doses. Here, we report the results of this clinical study, which is the first gene therapy trial performed in patients with AIP, and the first to employ an AAV5-based gene therapy product.
METHODS

Gene therapy vector
Vector design and production methodologies have already been described (20, 21) . The titer of the virus was determined by quantitative PCR and expressed as genome copies/ml (gc/ml) (21) .
Trial design and objectives
The study was designed as a phase 1, open-label, dose-escalation clinical trial.
Since AIP is a rare disease and its clinical presentation very heterogeneous, each patient served as his/her own control. Thus, the study comprised two different phases ( Figure   1 ); one pre-therapy and the other post-therapy (observational and interventional phases, respectively). The safety and the efficacy of the treatment were assessed comparing clinical and biochemical parameters of the observational and interventional phases.
The primary objective was to assess the safety of the treatment. Secondary objectives were to assess the effect of the treatment on ALA and PBG urinary levels, the clinical evolution of the disease, health-related quality of life, and psychological disturbances.
Patients were included and followed-up in two Spanish centers, Clínica
Universidad de Navarra (Pamplona) and Hospital 12 de Octubre (Madrid). All patients received the treatment at Clínica Universidad de Navarra.
Inclusion and exclusion criteria
Only patients with at least 2 hospital admissions caused by AIP acute attacks or 4 admissions for AIP-specific treatment in the year prior to the initiation of the trial were included. Exclusion criteria were the presence of liver disease including hepatitis C or B viral infection, cirrhosis and hepatocellular carcinoma, advanced renal failure, and presence of neutralizing antibodies against the vector. Participation in the observational phase for at least 6 months immediately prior to treatment was required in order to be included in the interventional phase. Complete inclusion and exclusion criteria are provided in Supplementary Table 1 .
Study procedures
Observational phase. At the selection visit, patients were evaluated by complete medical history including AIP-specific events such as hospital admissions in the 12 months prior inclusion and AIP-specific therapies, physical examination, blood tests 
Laboratory studies
ALA and PBG determination in urine sample were performed in a centralized laboratory at Porphyria Centre Sweden, Karolinska University Hospital (Stockholm, Sweden). Routine blood tests were performed at local laboratories (Hospital 12 de
Octubre and Clínica Universidad de Navarra).
Detection of vector DNA sequence in liver samples
Needle liver biopsies were obtained from 6 patients 1 year after treatment.
Biopsies were frozen in isopentane cooled with liquid nitrogen. Genomic DNA and total RNA was isolated from liver biopsies using the DNeasy Blood and Tissue Extraction Kit (Qiagen) and QIAamp RNA Tissue Extraction mini kit. Primers specific for the boundary between the coPBGD sequences and the polyA element were used to amplify a sequence specific for the vector DNA and messenger RNA (mRNA) to differentiate it from the endogenous gene and nRNA as previously described (21) . To determine endogenous PBGD gene and mRNA copy number human PBGD specific primers were used. Real-time PCR-based quantification was performed using SYBR Green master mix (Applied Biosystems, Foster City, CA). Results were expressed as copy number per µg of total DNA or RNA. Upper Nornal Limit) one week after therapy. It coincided with an acute AIP attack and normalized once the attack had subsided (data not shown). A total of 4 severe adverse events were observed in 2 patients, however, none of them was related to either gene therapy or study procedures (Table 1) .
Immune responses
Patients were analyzed for total and neutralizing antibodies against AAV5 and total antibodies against the recombinant PBGD protein at different time points after vector administration. All developed antibodies against the AAV5 protein capsid capable of neutralizing AAV5 infectivity (Supplementary Figure 1) . In general the Table 3 ).
Viral shedding
We investigated the presence of the virus in serum, urine, stool, nasal secretion, saliva and semen. Vector shedding analysis in serum showed maximum vector concentrations 8 hours after therapy (Supplementary Figure 2) . Titers declined thereafter to become undetectable by day 30 post-injection. Very low levels of rAAV2/5-PBGD could be transiently detected in saliva, urine, nasal secretion and faeces, but was undetectable in all patients by day 30. Importantly, no vector was detected in semen samples, excluding the risk of germ line transmission in those patients (Supplementary Figure 2) .
ALA and PBG levels, requirement of AIP-specific therapies and hospitalizations
Patients showed high levels of urinary ALA and PBG both during the observational and interventional phases of the study and no significant changes were observed after rAAV2/5-PBGD administration ( Figure 3A and B) .
However, a trend towards decreased heme replacement therapy was observed in the interventional phase compared to the observational period ( Figure 4A ). In parallel the number and duration of hospitalizations also decreased after therapy ( Figure 
Depression, Anxiety and Quality of life
Patients showed a significant improvement of the depression score (BDI-II) after therapy in comparison to the observational phase ( Figure 5A ) and the anxiety score (BAI-I questionnaire) was ameliorated in 7 patients and remained unchanged in one case, Patient 3, ( Figure 5B ). Moreover, the SF 36 questionnaire, which evaluates patient health status and overall quality of life, revealed a significant amelioration of the mental status following therapy and a better score for physical parameters in 7 patients ( Figure   5C and D).
Liver transduction
One year after vector administration 6 out of 8 patients volunteered to have a liver biopsy for the evaluation of tissue transduction. Vector genomes were detected in the liver of all tested patients albeit the copy number was unrelated to the vector dose (Table 2) 
DISCUSSION
In AIP the liver is responsible for excessive production and accumulation of toxic heme precursors, thus playing a key role in the development of clinically active disease. This notion is supported by the fact that liver transplantation results in complete metabolic correction of AIP (19) . However, transplantation is associated with many complications and requires life-long immunosuppressive therapy (19) . There clearly is a need for patients with severe AIP for less invasive therapeutic options before neurological sequelae become irreversible. In AIP mice transduction of hepatocytes with gene therapy vectors encoding PBGD prevented acute attacks upon phenobarbital administration, suggesting gene therapy as a promising approach for the treatment of AIP (20, (22) (23) (24) . Based on these observations we tested rAAV2/5-PBGD in increasing intravenous doses in 8 AIP patients divided into 4 cohorts (2 subjects each) from 5x10 11 (cohort A) to 1.8x10 13 gc/kg (cohort D). All patients included in the study had at least 2 hospital admissions and/or 4 courses of AIP-specific therapies for acute attacks in the year previous to the inclusion visit. Most trial participants had a very severe form of the disease with chronic symptoms and frequent bouts of symptomatic aggravation requiring heme replacement therapy. Our study shows that the therapy was well tolerated. No serious adverse events related to the AAV5-based vector administration were observed. As expected all patients generated neutralizing anti-AAV5 antibodies after therapy but, notably, we could not detect any cellular immune response -neither against the transgene nor against the vector capsid. In accordance with the absence of a cellular immune response against the vector capsid proteins, no transaminase elevation was observed. This was in contrast to findings in two previous liver-directed gene therapy trials using AAV serotypes 2 (25, 26) and 8 (27) in which the patients experienced elevations of serum transaminases between 6 to 8 weeks after therapy, likely due to T cell response against AAV capsid antigen present in transduced hepatocytes. This led to abrogation or reduction of transgene expression in the first study and to the use of steroid therapy to preserve the transduced cells in the second study. Interestingly, the doses of vector employed in the hemophilia trials were nearly 10-fold lower that the ones employed in our study, the highest dose being 2x10 12 gc/kg while in our trial the highest dose was 1.8x10 13 gc/kg. The absence of liver damage and anti-capsid T cell immunity in the present AIP gene therapy trial could be due to scant immunogenicity of AAV5 compared to AAV2 and AAV8 or to low liver transduction at the doses used. There are structural differences between AAV5 and other serotypes, that can explain the different antigenicity of this vector. Indeed according to amino acid sequencing data, AAV5 shares less than 60% of the sequences of AAV2 and AAV8, while the last two serotypes share more than 80% of amino acid sequence identity (28) .
An important safety issue of AAV-based gene therapy is the potential genotoxicity of the vector. This point has been strongly debated. Donsante et al. (29) showed that treatment of beta-glucuronidase-deficient mice with a therapeutic AAV vector in the neonatal period of life was followed by increased incidence of HCC.
Similarly, Chandler et al. reported a high incidence of HCC in a mouse model of methyl-malonic acidemia, however, they also showed that vector dose, the type enhancer/promoter, and the timing of gene delivery are critical factors for determining HCC incidence (30) . Furthermore, several other independent and larger studies in adult mice showed lack of carcinogenicity of AAV therapeutic vectors (31) . However, recently Nault et al. reported the presence of integrated wild type (wt) AAV genomes in HCC samples in 11 out of 193 patients (32) . In our trial AAV vector was detected in liver biopsies in the six patients tested one year after therapy but integration analysis using an improved Multiplex LAM-PCR covering internal and external vector breakage sites showed that integrations were scarce and randomly distributed (33) and none of them involved the oncogenic regions reported by Nault et al. (32) .
At the vector doses used in the present trial we did not succeed in reducing ALA and PBG levels. Preclinical studies in AIP mice showed that therapeutic efficacy with rAAV2/5-PBGD was attained only at the dose of 1.25x10 13 gc/kg (20) which was similar to the highest one used in the present study. On the other hand, data from nonhuman primates (21) indicated that in order to raise PBGD enzymatic activity in liver tissue over endogenous levels it was necessary to use a rAAV2/5-PBGD dose of 5x10 
